BriaCell Transfers Soluble CD80 License to BriaPro; Four Posters Accepted at AACR 2026
Mar 10, 2026
BriaCell Therapeutics announced an asset purchase agreement transferring its Soluble CD80 license to majority-owned subsidiary BriaPro, while four abstracts were accepted for presentation at the 2026 AACR Annual Meeting.